Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS) SHH

Currency In CNY

AD

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

Address

Zhong Xin Mansion

Tianjin, 300193

China

Phone

86 22 2702 0892

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

4619

First IPO Date

June 06, 2001

Key Executives

NameTitlePayYear Born
Jian MaChief Financial Officer1.1M1978
Mingjie ShangEmployee Director1.17M1969
Yu ZhangChief Manufacturing Officer1.26M1973
Hong ZhouDeputy GM, Chief Engineer & Executive Director1.41M1970
Lei WangChairman of the Board2.36M1971
Min GuoExecutive Director01971
Yan JiaoSecretary to the Board of Directors01977
Hong ChenExecutive Vice President01971
Tang ChaoAccounting Supervisor0N/A
AD

Description

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, along with its subsidiaries, primarily manufactures and markets traditional Chinese medicine, Western pharmaceuticals, and various healthcare products within the People's Republic of China. Its business activities are structured into two distinct divisions: Chinese Medicine and Western Medicine. The company's operations extend beyond its core offerings to include the production and distribution of Chinese, Western, and biological pharmaceutical items. It also engages in the wholesale and retail trade of medicines, biochemical pharmaceutical products, and everyday consumer goods, in addition to managing hospitals. Furthermore, Tianjin Pharmaceutical Da Ren Tang provides a comprehensive suite of services such as logistics, inventory management, equipment installation, and drug processing. It also offers pharmaceutical inspection, testing, and advisory services. In terms of its commercial model, the company supplies its proprietary branded medicinal products directly to wholesalers. Conversely, it acquires pharmaceuticals marketed under other brands from distributors, subsequently reselling these to other wholesale clients. Established in 1992 and based in Tianjin, People's Republic of China, the company was previously known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited before adopting its current name in May 2022.

AD